Since its inception, Basilea Pharmaceutica has been pushing its drug delivery programs forward internally, but has been silent on the deal making front. Consequently, Basilea entered into its first alliance to develop its Phase III MRSA cephalosporin antibiotic with Johnson & Johnson company Cilag, which could worth a substantial sum of money to loss-making Basilea. Despite Roche’s rejection of the MRSA drug, Basilea has succeeded in attracting a major pharmaceutical company for marketing the compound.